Aimmune Therapeutics Inc (NASDAQ:AIMT) – Wedbush raised their Q1 2018 earnings estimates for shares of Aimmune Therapeutics in a research report issued to clients and investors on Wednesday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will earn ($0.72) per share for the quarter, up from their prior estimate of ($0.73). Wedbush has a “Outperform” rating and a $72.00 price objective on the stock. Wedbush also issued estimates for Aimmune Therapeutics’ Q2 2018 earnings at ($0.73) EPS, Q3 2018 earnings at ($0.73) EPS, Q4 2018 earnings at ($0.74) EPS, FY2018 earnings at ($2.92) EPS, FY2019 earnings at ($2.63) EPS, FY2020 earnings at ($0.06) EPS, FY2021 earnings at $3.46 EPS and FY2022 earnings at $9.93 EPS.
Other equities analysts also recently issued reports about the stock. Credit Suisse Group set a $45.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, January 11th. Roth Capital lifted their price target on shares of Aimmune Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. BidaskClub raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Cantor Fitzgerald reissued a “buy” rating on shares of Aimmune Therapeutics in a report on Tuesday, February 20th. Finally, Deutsche Bank set a $30.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $57.22.
Several large investors have recently modified their holdings of the company. MetLife Investment Advisors LLC bought a new position in Aimmune Therapeutics during the 4th quarter worth approximately $646,000. Glenmede Trust Co. NA bought a new position in Aimmune Therapeutics during the 4th quarter worth approximately $661,000. Raymond James & Associates boosted its stake in Aimmune Therapeutics by 7.2% during the 4th quarter. Raymond James & Associates now owns 24,737 shares of the biotechnology company’s stock worth $936,000 after acquiring an additional 1,669 shares during the last quarter. Franklin Resources Inc. bought a new position in Aimmune Therapeutics during the 4th quarter worth approximately $18,702,000. Finally, Highland Capital Management LP bought a new position in Aimmune Therapeutics during the 4th quarter worth approximately $5,663,000. Institutional investors own 62.04% of the company’s stock.
In other news, insider Susan E. Barrowcliffe sold 75,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $37.14, for a total transaction of $2,785,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Eric Bjerkholt purchased 3,125 shares of the stock in a transaction dated Monday, February 26th. The shares were acquired at an average price of $32.00 per share, with a total value of $100,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 58,093 shares of company stock valued at $1,858,976 and sold 133,968 shares valued at $5,073,180. Company insiders own 24.56% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Wedbush Research Analysts Lift Earnings Estimates for Aimmune Therapeutics Inc (AIMT)” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://stocknewstimes.com/2018/03/19/wedbush-research-analysts-lift-earnings-estimates-for-aimmune-therapeutics-inc-aimt.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.